Please login to the form below

Not currently logged in
Email:
Password:

Abbott loses pharma chief to Pierre Fabre

Olivier Bohuon, president of Abbott's pharmaceutical division, is leaving the company to join Pierre Fabre Group as CEO, effective September 1

Olivier Bohuon, president of Abbott's pharmaceutical division, is leaving the company to return to his native France as chief executive officer at Pierre Fabre Group, effective September 1. He will take over from former GlaxoSmithKline (GSK) CEO, Jean-Pierre Garnier.

Garnier took the reins at Pierre Fabre just two years ago, after retiring from GSK amid criticism from investor groups over the company's weak stock performance. His departure from the French firm was announced last week.

With Bohuon's exit, Abbott loses one of the company's key executives, a pharmacist and MBA who oversaw a division that is responsible for bringing in more than half of the company's annual sales.

Bohuon, who was based in Abbott's Chicago offices, was hired by Abbott as president for European operations in 2003 and was then promoted to president of Abbott International. He joined Abbott from GSK, where he had been director of Commercial Operations, Europe.

The Pierre Fabre Group, which is focused on the dermatology and cosmetic markets, is the second-largest independent French pharmaceutical company, with sales of about €1.8bn. Bohuon will also serve as president of Pierre Fabre Medicament, the pharmaceuticals branch of Pierre Fabre Group, which has been investing heavily in research and development in oncology, psychiatry, urology, cardiovascular health and rheumatology.

Richard A Gonzalez, who was Abbott's president and chief operating officer until his retirement three years ago, will take over Bohoun's duties at Abbott on an interim basis until a replacement is found. Gonzalez has been heading up Abbott Ventures, an investment division at the company, since last year.

6th July 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GK Strategy

GK is award-winning independent communications agency specialising in delivering impactful strategies for clients across the healthcare market....

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...

Infographics